Skip to main content
SpringerLink
Log in

Carbamylated Erythropoietin Alleviates Kidney Damage in Diabetic Rats by Suppressing Oxidative Stress

  • Published:
Current Medical Science Aims and scope Submit manuscript

Summary

The oxidative stress response plays an important role in the occurrence and development of diabetic kidney disease (DKD). It has become a new treatment target for DKD. In the current study, the effects of carbamylated erythropoietin (CEPO) on renal oxidative stress and damage in diabetic rats were examined. Thirty Sprague Dawley rats were intraperitoneally administered with 60 mg/kg streptozotocin to establish the diabetes model. The diabetic rats were randomly allocated into 4 groups (n=6 each): diabetes model group (DM group), DM + CEPO treatment group (DC group), DM + CEPO + EPO receptor (EPOR) blocking peptide treatment group (DCEB group), and DM + CEPO + CD131 blocking peptide treatment group (DCCB group). Meanwhile, a normal control group (NC group, n=6) was set up. Kidney tissues and blood samples were obtained for evaluation of oxidative stress and renal function. The results showed that diabetic rats exhibited increased oxidative stress in the kidney and early pathological changes associated with DKD. Treatment with CEPO reduced oxidative stress and attenuated renal dysfunction. However, diabetic rats treated with the combination of CEPO and EPOR blocking peptide or CD131 blocking peptide showed increased oxidative stress and reduced renal function when compared with CEPO treatment alone group. These results suggested that CEPO can protect against kidney damage in DKD by inhibiting oxidative stress injury via EPOR-CD131 heterodimers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sanajou D, Ghorbani Haghjo A, Argani H, et al. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions. Eur J Pharmacol, 2018,833:158–164

    Article  CAS  Google Scholar 

  2. Kajal A, Singh R. Coriandrum sativum seeds extract mitigate progression of diabetic nephropathy in experimental rats via AGEs inhibition. PLoS One, 2019, 14(3):e0213147

    Article  CAS  Google Scholar 

  3. Guerin-Dubourg A, Cournot M, Planesse C, et al. Association between Fluorescent Advanced Glycation End-Products and Vascular Complications in Type 2 Diabetic Patients. Biomed Res Int, 2017,2017:7989180

    Article  Google Scholar 

  4. Abdel-Moneim A, Mahmoud B, Nabil A, et al. Correlation between oxidative stress and hematological profile abnormalities in diabetic nephropathy. Diabetes Metab Syndr, 2019,13(4):2365–2373

    Article  Google Scholar 

  5. Villegas-Rivera G, Roman-Pintos LM, Cardona-Munoz EG, et al. Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Oxid Med Cell Longev, 2015, 2015:756294

    Article  Google Scholar 

  6. Lazavi F, Mirmiran P, Sohrab G, et al. The barberry juice effects on metabolic factors and oxidative stress in patients with type 2 diabetes: A randomized clinical trial. Complement Ther Clin Pract, 2018,31:170–174

    Article  Google Scholar 

  7. Hwang YC, Kim SW, Hur KY, et al. Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study. J Korean Med Sci, 2019,34(15):e117

    Article  Google Scholar 

  8. Lee EY, Lee MY, Hong SW, et al. Blockade of oxidative stress by vitamin C ameliorates albuminuria and renal sclerosis in experimental diabetic rats. Yonsei Med J, 2007,48(5):847–855

    Article  CAS  Google Scholar 

  9. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J, 2013,15(1):195–218

    Article  CAS  Google Scholar 

  10. Takayanagi R, Inoguchi T, Ohnaka K. Clinical and experimental evidence for oxidative stress as an exacerbating factor of diabetes mellitus. J Clin Biochem Nutr, 2011,48(1):72–77

    Article  CAS  Google Scholar 

  11. Bhoopalan SV, Huang LJ, Weiss MJ. Erythropoietin regulation of red blood cell production: from bench to bedside and back. F1000Res, 2020,18(9):1153

    Article  Google Scholar 

  12. Kittur FS, Lin Y, Arthur E, et al. Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation. Biochem Biophys Rep, 2019,17:157–168

    PubMed  PubMed Central  Google Scholar 

  13. Hache G, Garrigue P, Bennis Y, et al. ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors’ Angiogenic Potential and Homing Ability. Shock, 2016,46(4):390–397

    Article  CAS  Google Scholar 

  14. Huang CT, Chen SH, Lin SC, et al. Erythropoietin reduces nerve demyelination, neuropathic pain behavior and microglial MAPKs activation through erythropoietin receptors on Schwann cells in a rat model of peripheral neuropathy. Glia, 2018,66(11):2299–2315

    Article  Google Scholar 

  15. Lee BJ, Jun HO, Kim JH, et al. Astrocytic cystine/glutamate antiporter is a key regulator of erythropoietin expression in the ischemic retina. Faseb J, 2019,33(5): 6045–6054

    Article  CAS  Google Scholar 

  16. Oshima N, Onimaru H, Yamagata A, et al. Erythropoietin, a putative neurotransmitter during hypoxia, is produced in RVLM neurons and activates them in neonatal Wistar rats. Am J Physiol Regul Integr Comp Physiol, 2018,314(5):R700–R708

    Article  CAS  Google Scholar 

  17. Elliot-Portal E, Laouafa S, Arias-Reyes C, et al. Brain-derived erythropoietin protects from intermittent hypoxia-induced cardiorespiratory dysfunction and oxidative stress in mice. Sleep, 2018,41(7):1–13

    Article  Google Scholar 

  18. Elshiekh M, Kadkhodaee M, Seifi B, et al. Additional effects of erythropoietin pretreatment, ischemic preconditioning, and N-acetylcysteine posttreatment in rat kidney reperfusion injury. Turk J Med Sci, 2019,49(4): 1249–1255

    Article  CAS  Google Scholar 

  19. Siems W, Carluccio F, Radenkovic S, et al. Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. Kidney Blood Press Res, 2005,28(5–6):295–301

    Article  CAS  Google Scholar 

  20. Bartnicki P, Fijalkowski P, Majczyk M, et al. Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease. Med Sci Monit, 2013,19:954–959

    Article  Google Scholar 

  21. Hemani S, Lane O, Agarwal S, et al. Systematic Review of Erythropoietin (EPO) for Neuroprotection in Human Studies. Neurochem Res, 2021,46(4):732–739

    Article  CAS  Google Scholar 

  22. Mun KC, Golper TA. Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purif, 2000,18(1):13–17

    Article  CAS  Google Scholar 

  23. Jo HR, Kim YS, Son H. Erythropoietin and carbamylated erythropoietin promote histone deacetylase 5 phosphorylation and nuclear export in rat hippocampal neurons. Biochem Biophys Res Commun, 2016,470(1):220–225

    Article  CAS  Google Scholar 

  24. Boesch S, Nachbauer W, Mariotti C, et al. Safety and tolerability of carbamylated erythropoietin in Friedreich’s ataxia. Mov Disord, 2014,29(7):935–939

    Article  CAS  Google Scholar 

  25. Dorotea D, Kwon G, Lee JH, et al. A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats. Pharmacology, 2018,102(3–4):180–189

    Article  CAS  Google Scholar 

  26. Ilatovskaya DV, Blass G, Palygin O, et al. A NOX4/TRPC6 Pathway in Podocyte Calcium Regulation and Renal Damage in Diabetic Kidney Disease. J Am Soc Nephrol, 2018,29(7):1917–1927

    Article  CAS  Google Scholar 

  27. Wang Y, Li Y, Yang Z, et al. Pyridoxamine Treatment of HK-2 Human Proximal Tubular Epithelial Cells Reduces Oxidative Stress and the Inhibition of Autophagy Induced by High Glucose Levels. Med Sci Monit, 2019,25:1480–1488

    Article  CAS  Google Scholar 

  28. Diab El-Harakeh M, Njeim R, Youssef A, et al. Novel triazine-based pyrimidines suppress glomerular mesangial cells proliferation and matrix protein accumulation through a ROS-dependent mechanism in the diabetic milieu. Bioorg Med Chem Lett, 2019,29(13): 1580–1585

    Article  CAS  Google Scholar 

  29. Cheng YS, Chao J, Chen C, et al. The PKCbeta-p66shc-NADPH oxidase pathway plays a crucial role in diabetic nephropathy. J Pharm Pharmacol, 2019;71(3):338–347

    Article  CAS  Google Scholar 

  30. Østergaard JA, Cooper ME, Jandeleit-Dahm KAM. Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease. J Nephrol, 2020,33(5):917–929

    Article  Google Scholar 

  31. Miller JL, Church TJ, Leonoudakis D, et al. Discovery and Characterization of Nonpeptidyl Agonists of the Tissue-Protective Erythropoietin Receptor. Mol Pharmacol, 2015,88(2):357–367

    Article  CAS  Google Scholar 

  32. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA, 2004,101(41):14907–14912

    Article  CAS  Google Scholar 

  33. Bennis Y, Sarlon-Bartoli G, Guillet B, et al. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J Thromb Haemost, 2012,10(9):1914–1928

    Article  CAS  Google Scholar 

  34. Um M, Gross AW, Lodish HF. A “classical” homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal, 2007,19(3):634–645

    Article  CAS  Google Scholar 

  35. Hahn N, Knorr DY, Liebig J, et al. The Insect Ortholog of the Human Orphan Cytokine Receptor CRLF3 Is a Neuroprotective Erythropoietin Receptor. Front Mol Neurosci, 2017,10:223

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Geriatrics, Renmin Hospital of Wuhan University, Wuhan, 430060, China

    Jian-zhong Dang & Ying-jie Yang

  2. Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, 430060, China

    Ya-fang Tu & Juan Wang

Authors
  1. Jian-zhong Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ya-fang Tu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying-jie Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian-zhong Dang.

Ethics declarations

The authors declare that they have no conflict of interest.

Additional information

This work was supported by the National Natural Sciences Foundation of China (No. 81500639) and the Science Foundation of Hubei Society of Microcirculation (No. 2019HX0020).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dang, Jz., Tu, Yf., Wang, J. et al. Carbamylated Erythropoietin Alleviates Kidney Damage in Diabetic Rats by Suppressing Oxidative Stress. CURR MED SCI 41, 513–521 (2021). https://doi.org/10.1007/s11596-021-2370-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-021-2370-x

Key words

Search

Navigation